Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

Company's End-of-Phase II Meeting with FDA Set for Sept. 29

LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead AMPA/kainate-type glutamate receptor antagonist, tezampanel, demonstrated improvement on important secondary endpoints in a 306-patient Phase IIb clinical trial in acute migraine headache. Specifically, tezampanel demonstrated improvement in the following secondary endpoints: sustained headache response, absence of nausea or vomiting, absence of phonophobia and absence of photophobia.

"This is our second positive study in acute migraine with tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics, who presented the data. "In both studies, we have shown improvement in all of the endpoints that the FDA has indicated will be required for the drug's approval. Earlier this year we conducted a clinical guidance call with the FDA in which the agency said it has no objection with us moving forward with a Phase III study of the 40 mg dose of tezampanel. We have scheduled an end-of-Phase II meeting to discuss the entire Phase III program with the agency on Sept. 29."

In the Phase IIb clinical trial, tezampanel was well tolerated with no reports of serious or medically important adverse events. At the 40 mg dose, the most commonly reported adverse events compared to placebo were injection site pain (5.1 percent vs. 20 percent), injection site burning (3.8 percent vs. 6.7 percent), dizziness (6.4 percent vs. 5.3 percent), somnolence (7.7 percent vs. 6.7 percent) and dry mouth (2.6 percent vs. 5.3 percent). As indicated above, the reported rates of "injection site pain," "injection site burning" and "dry mouth" occurred more frequently in the placebo group.

Tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for chronic pain, including migraine. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosis and epilepsy.

Migraine is a debilitating neurological condition characterized by an intense and disabling episodic headache. According to the National Headache Foundation, nearly 30 million people in the United States suffer from migraines. More than 50 percent of migraine sufferers endure from one to four migraine attacks per month. In addition to headache pain, migraine attacks are frequently accompanied by photophobia, phonophobia, nausea and vomiting.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel as a treatment for migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosis and epilepsy. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements, including whether any preclinical studies or clinical trials conducted in the future, will prove successful, and if successful, whether the results can be replicated. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact:

Paul Schneider

TorreyPines Therapeutics, Inc.

858-623-5665, x125

Media Contact:

David Schull

Russo Partners, LLC


Investor Contact:

Rhonda Chiger

Rx Communications


SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
(Date:12/1/2015)... , Dec. 1, 2015 Breg, Inc ... services, announced today that it has been awarded three ... Members served by Novation will have access to improved ... bracing products and soft goods dedicated to advancing orthopedic ... The aging U.S. population, rising prevalence of chronic ...
(Date:12/1/2015)... , Dec. 1, 2015 Building ... HIV/AIDS, Johnson & Johnson (NYSE: JNJ ) ... Janssen Pharmaceutical Companies to significantly reduce the burden ... make up 74 percent of new HIV infections ... on World AIDS Day, these new initiatives include ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been awarded a fixed price per sprint agile development contract to support ... $34 million over five years, provides software engineering, infrastructure, as well as operations ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 ... semi-finalists to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic ... Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
Breaking Medicine News(10 mins):